FORWARD FEATURES CALENDAR

Find us on

Latest News

Albéa, an affiliate of Sun European Partners, has completed the acquisition of Rexam Personal Care, Cosmetic division, a producer of dispensing systems and make up packaging for the cosmetic and personal care markets.  The division operates 11 plants in Europe, the Americas and Asia. This follows Rexam’s announcement on 3 July 2012 on the proposed sale of its personal care business.   With this new acquisition, Albéa expands its packaging solutions to dispensing systems and reinforces its offer in tubes, cosmetic rigid packaging, and beauty solutions. It also strengthens Albéa’s position in emerging markets to develop its wide product portfolio
Water Street Healthcare Partners, a private equity firm focused exclusively on the healthcare industry, has sold Precision Dynamics Corporation (PDC) to Brady Corporation in a cash transaction for USD300m, subject to customary working capital and post-close adjustments. Water Street divested PDC after spending five years building the company into a global leader in patient safety identification (ID) through a combination of strategic acquisitions and organic initiatives. Headquartered in Valencia, California, PDC designs and manufactures products used by hospitals across the US to reduce medical errors, and integrate and share patient data. Water Street partnered with PDC’s founders and management team
Private equity firm GTCR has completed the acquisition of Correctional Healthcare Companies (CHC), an outsourced healthcare provider to correctional facilities. GTCR is partnering with CHC chief executive Doug Goetz, chief operating officer Don Houston and managed care industry executive Dale Wolf to grow and expand the business. This investment results from GTCR’s proactive efforts with Wolf and Jessamine Healthcare, a management startup with Wolf, targeted at a range of healthcare cost containment and payor businesses. Wolf, former chief executive of Coventry Health Care, has joined CHC as executive chairman as part of the transaction. CHC provides inmate healthcare services to
JHP Pharmaceuticals, a pharmaceutical company that acquires, develops, manufactures and sells sterile injectable products, has been acquired by an affiliate of private equity firm Warburg Pincus. The company was acquired from JHP Holdings, an entity majority-owned by Morgan Stanley Principal Investments, for USD195m on a debt-free, cash-free basis.  JHP’s current management team will continue to hold an interest in the company. Since its founding in 2007, JHP has developed into a leading specialty pharmaceutical company focused on the USD30bn US sterile injectable drug market. JHP’s market presence, high-quality sterile manufacturing facility, and experienced management team, coupled with growth capital and
Independent financial advisory and investment banking firm Duff & Phelps is to be acquired by a consortium comprising controlled affiliates of or funds managed by The Carlyle Group, Stone Point Capital, Pictet & Cie and Edmond de Rothschild Group for USD15.55 per share in cash in a transaction valued at approximately USD665.5m. The offer represents a 19.2 per cent premium to the closing price of Duff & Phelps shares on 28 December 2012, and 27.3 per cent over the company’s volume weighted average share price during the 30 days ended 28 December 2012. The transaction is expected to close in
Affiliates of US Joiner have acquired JCI Metal Products, a provider of maintenance, repair and overhaul (MRO) services focused on habitability, fabrication, electrical and piping solutions to US Navy vessels.  JCI is headquartered in San Diego, California with additional operations in Pearl Harbor, Hawaii. The acquisition will enable US Joiner to further establish its position in the US Navy MRO market and expand its footprint in the Pacific. US Joiner is an independent domestic provider of turnkey marine joiner and furniture solutions for US Government and commercial customers. Headquartered in Crozet, Virginia, the company also has existing facilities in San
ClearMomentum, a provider of private equity portfolio management software, has appointed Dan Dykens as the company’s new president and chief executive. With nearly two decades of experience in the financial technology and hedge fund industries, Dykens (pictured) replaces ClearMomentum founder and CEO John Grabski, who will continue to serve as the company’s chairman of the board. "After searching for nearly two years for a CEO candidate with deep domain expertise, leadership skills and a passion for customer service, we successfully engaged with one of the most talented CEOs in the industry," says Grabski. "We could not be more pleased with
India flag
Private equity firms invested USD8,853m over 406 deals in India during the 12 months ending December 2012, compared to the USD10,378m across 483 deals during the previous year, according to analysis by Venture Intelligence. These figures – which include VC investments and exclude PE investments in real estate – take the total investments by PE firms over the past five years to about USD41.4bn across 2,036 transactions. The latest Venture Intelligence data reveals that PE investments in October-December 2012 declined by over 32 per cent to about USD1,010m (across 82 deals) compared to the USD1,490m invested (across 121 deals) in
Handshake 2
Private equity firm Crestview Partners has acquired NEP Broadcasting, LLC and its affiliates from American Securities. Financial terms of the transaction have not been disclosed.  NEP is an international provider of outsourced tele-production services critical to the delivery of live sports and entertainment events. NEP enables its clients to execute, deliver, and display productions on any platform.  NEP’s global headquarters is located in Pittsburgh, Pennsylvania, and the company also maintains a headquarters in the United Kingdom to serve its European customers. Jeff Marcus, Partner at Crestview and head of the firm’s media strategy, says: "We have followed NEP’s performance since 2006 and
Trevi Therapeutics has announced the closing of a USD10 million Series A financing to advance the clinical development of T111 in the lead indication of uremic pruritus. The Series A investment was completed with TPG Biotech, the life science venture investment arm of TPG which had previously made a seed investment in the Company. With the proceeds from the Series A investment, Trevi intends to advance T111, an oral extended release opioid with a unique agonist/antagonist mechanism of action, into clinical development for the treatment of uremic pruritus. Uremic pruritus is a persistent and debilitating itching in patients on dialysis

Special Reports

Featured

Events

12 November, 2026 – 8:00 am

Directory Listings